13 results about "GPR120" patented technology

The invention relates to the field of microorganisms, in particular to application of a microbial strain in preparation of a medicine for preventing or treating metabolic diseases, the microbial strain belongs to Enterococcus canini, and the metabolic diseases comprise diabetes, obesity, obesity-related diseases and metabolic syndromes. According to the present invention, with the application of the Enterococcus canintestini, the target spots GPR120 and MC4R for the treatment of obesity diabetes can be significantly activated; the weight, fasting blood glucose, area under a glucose tolerance curve and area under an insulin tolerance curve of obese mice can be reduced, the content of free fatty acid in plasma, total cholesterol in liver and low-density lipoprotein-cholesterol in liver can be reduced, and the content of glucagon-like peptide-1 in plasma and the content of high-density lipoprotein-cholesterol in liver can be increased.

The invention discloses a strain of lactobacillus acidophilus for treating chronic cerebral ischemia, which is preserved in the China Center for Type Culture Collection (CCTCC) and has the preservation number of CCTCC NO: M 20251505. Animal experiments show that the strain can reduce the death rate of chronic cerebral ischemia model mice and improve neurological impairment, motion coordination and spatial learning and memory ability of the chronic cerebral ischemia model mice. Mechanism research shows that the strain can increase histone acetylation and BDNF secretion by inhibiting the activity of astrocyte HDAC1, and meanwhile, can inhibit an NF-kappa B signal channel and reduce inflammatory factor release by activating a microglial cell GPR120 receptor, so that a neuroprotective effect is achieved through an'intestine-brain axis'. The invention provides a new candidate strain for the development of microbial preparations for preventing and / or treating chronic cerebral ischemia and related cognitive impairment.

A flavor composition comprising at least one compound that modulates, increases and / or enhances the activity of a GPR120 fatty acid receptor that can be used to enhance the fatty acid taste and / or palatability of pet food products is described herein. Also disclosed herein are methods for identifying said compounds.

The present invention relates to GPR120 agonists for use in the treatment of inflammatory bowel disease, in particular ulcerative colitis or Crohn's disease.

The application relates to the technical field of animal nutrition and meat quality regulation, and particularly relates to application of vascular endothelial growth factor B (VEGF-B) in increasing intramuscular fat content of pigs. The content of VEGF-B in pig serum and the expression level of VEGF-B in skeletal muscle tissue are significantly positively correlated with the intramuscular fat content of pigs, so that VEGF-B can be used as a biomarker for predicting the intramuscular fat content of pigs; meanwhile, fish oil rich in n-3 polyunsaturated fatty acids can promote the expression level of VEGF-B by activating G protein-coupled receptor 120 (GPR120), then increase the transvascular endothelial transport of fatty acids in blood vessels to skeletal muscle, and finally increase the intramuscular fat content.

The application describes a method for diagnosing and / or monitoring the progress of acute kidney damage, wherein in a urine sample the concentration of at least one G-protein-coupled receptor, selected from GPR40, GPR43, GPR91 and GPR120, is measured and compared with a normal value. It also describes the use of these G-protein-coupled receptors in this method, and these G-protein-coupled receptors for use in such a method.

The application describes a method for diagnosing and / or monitoring acute kidney injury, in which the concentration of at least one G-protein-coupled receptor selected from GPR40, GPR43, GPR91, and GPR120 is measured in a urine sample and compared to a normal value. Furthermore, the application describes the use of these G-protein-coupled receptors in this method and these G-protein-coupled receptors for use in such a method.

The application discloses application of a GPR120 agonist in preventing or treating intestinal-liver immunological injury induced by poultry acetochlor poisoning. According to the intestinal-liver toxicity of chicken acetochlor, the normal expression of G protein-coupled receptor 120 is mainly changed. Subsequently, programmed cell death occurs in the intestinal tract and the liver, and a large amount of inflammatory factor release is caused; the intestinal-liver axis immunological injury is improved by activating the G protein-coupled receptor 120 in vivo and in vitro, so as to rescue the chicken acetochlor poisoning reaction. The application provides a prevention and treatment basis for poultry acetochlor poisoning immunological injury diseases, provides medical data for developing poultry immunological activity drugs or supplements, and also provides more technical means for developing and utilizing environment-friendly, efficient, targeted and slow-release new veterinary drug preparations.

The invention discloses an application of a GPR120 / FFAR4 agonist TUG-891 in preparation of drugs for treating diabetes and periodontitis syndrome, and by integrating multi-tissue transcriptomics and bioinformatics analysis, it is found for the first time that GPR120 is a key target of diabetes complicated with periodontitis. In-vivo experiments prove that TUG-891 intervention not only can significantly improve systemic metabolic disorders (such as hyperglycemia and dyslipidemia) of diabetic model mice, but also can effectively relieve alveolar bone resorption caused by periodontitis, inhibit osteoclast activity and improve bone microstructure. A further mechanism research shows that the TUG-891 can relieve periodontal local inflammatory response by inhibiting neutrophil extracellular trap formation (NETosis). The invention provides a brand-new targeted therapy strategy for co-disease treatment of diabetes and periodontitis, and has important clinical transformation value.

The invention relates to the technical field of animal nutrition and meat quality regulation and control, in particular to application of a vascular endothelial growth factor B (VEGF-B) in increasing the fat content in pig muscle. The content of the VEGF-B in pig serum and the expression level of the VEGF-B in skeletal muscle tissue are in significant positive correlation with the fat content in the pig muscle, so that the VEGF-B can be used as a biomarker for predicting the fat content in the pig muscle; meanwhile, the fish oil rich in n-3 polyunsaturated fatty acids can promote the VEGF-B expression level by activating a G protein coupled receptor 120 (GPR120), so that the transvascular endothelial transport of fatty acids in blood vessels to skeletal muscles is increased, and finally the intramuscular fat content is increased.

The present disclosure relates to fatty acid mimetics, synthetic methods for preparing such compounds, and methods of using such compounds.

The present invention provides compositions and pharmaceutical compositions of GPR84 agonists and GPR120 agonists for us in the treatment of obesity and overweight. The invention provides methods of treatment accordingly as well as a kit for use in the treatment of obesity and overweight.

A flavor composition comprising at least one compound that modulates, increases and / or enhances the activity of a GPR120 fatty acid receptor that can be used to enhance the fatty acid taste and / or palatability of pet food products is described herein. Also disclosed herein are methods for identifying said compounds.